Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On May 12, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2025 that ended March 31, 2025.</li><li>Arrowhead is set up with multiple value drivers in both the near- and long-term.</li><li>Most importantly, the NDA for plozasiran for the treatment of familial chylomicronemia syndrome (FCS) is currently under review by the FDA and has a PDUFA date of November 18, 2025.</li></ul>

On May 12, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2025 that ended March 31, 2025.Arrowhead is set up with multiple value drivers in both the near- and long-term.Most importantly, the NDA for plozasiran for the treatment of familial chylomicronemia syndrome (FCS) is currently under review by the FDA and has a PDUFA date of November 18, 2025.

ARWR: 장기적 성장을 위한 다양한 가치 동인 